Pure class III agents for prevention of sudden cardiac death

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 9 SUPPL., 2003, Pages

  Pratt, Craig M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Antiarrhythmic; Azimilide; d,l sotalol; d sotalol; Dofetilide; Sudden death

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOFETILIDE; SOTALOL;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRESSLER SYNDROME; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SUDDEN DEATH;

EID: 0141853861     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.14.s9.15.x     Document Type: Conference Paper

References (18)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Effect of encainide and flecainide on mortality in a randomized trial of atrial suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
2. Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1:1142-1147.
3. Beta-blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with myocardial infarction: I. Mortality results. JAMA 1982;247:1707-1717.
4. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
5. Waldo AL, Camm AJ, Ruyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ, for the SWORD Investigators: Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD Trial). Am J Cardiol 1995;75:1023-1027.
6. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
7. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, Pitt B, Schwartz PJ, Veltri EP, Waldo AL, for the SWORD Investigators: Mortality in the Survival With Oral D-sotalol (SWORD). Why did patients die? Am J Cardiol 1998;81:869-876.
8. Sedgwick ML, Rasmussen HS, Cobbe SM: Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992;69:513-517.
9. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation and flutter. The Symptomatic Atrial Fibrillation Investigation Research on Dofetilide (SAFIRE-D) Study. Circulation 2000;102:2385-2390.
10. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999;341:857-865.
11. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ: Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction: a randomized trial. Lancet 2000;356:2052-2058.
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
13. Dofetilide (Tikosyn®) presentation at the Cardiorenal Advisory Board meeting of the Food and Drug Administration Norwegian Multicenter Study Group, January 14, 1999.
14. Pritchett ELC, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE: Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J Am Coll Cardiol 2000;36:794-802.
15. Camm AJ, Pratt CM, Schwartz PJ. Al-Khalidi HR, Spyt M, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM: Azimilide Post Infarct Survival Evaluation (ALIVE): Azimilide does not affect mortality in post-myocardial infarction patients. Circulation 2001;104:1B.
16. Pratt CM, Al-Khalidi HR, Brum JM, Camm AJ, Schwartz PJ, Holroyde MJ: Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial. Eur Heart J 2001;22:700.
17. Pratt CM, Singh SN, Al-Khalidi H, Brum JM, Holroyde MJ, de Ferrari GM, Schwartz PJ, Matteo PS, Camm JA: Efficacy of azimilide in treatment of atrial fibrillation in a high-risk post-myocardial infarction population. Circulation 2002;106:11-634.
18. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-2150.